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TMC114, a newly designed human immunodeficiency virus type 1 (HIV-1) protease inhibitor, is extremely
potent against both wild-type (wt) and multidrug-resistant (MDR) viruses in vitro as well as in vivo. Although
chemically similar to amprenavir (APV), the potency of TMC114 is substantially greater. To examine the basis
for this potency, we solved crystal structures of TMC114 complexed with wt HIV-1 protease and TMC114 and
APV complexed with an MDR (L63P, V82T, and I84V) protease variant. In addition, we determined the
corresponding binding thermodynamics by isothermal titration calorimetry. TMC114 binds approximately 2
orders of magnitude more tightly to the wt enzyme (Kd  4.5  10
12 M) than APV (Kd  3.9  10
10 M). Our
X-ray data (resolution ranging from 2.2 to 1.2 A˚) reveal strong interactions between the bis-tetrahydrofuranyl
urethane moiety of TMC114 and main-chain atoms of D29 and D30. These interactions appear largely
responsible for TMC114’s very favorable binding enthalpy to the wt protease (12.1 kcal/mol). However,
TMC114 binding to the MDR HIV-1 protease is reduced by a factor of 13.3, whereas the APV binding constant
is reduced only by a factor of 5.1. However, even with the reduction in binding affinity to the MDR HIV protease,
TMC114 still binds with an affinity that is more than 1.5 orders of magnitude tighter than the first-generation
inhibitors. Both APV and TMC114 fit predominantly within the substrate envelope, a property that may be
associated with decreased susceptibility to drug-resistant mutations relative to that of first-generation inhib-
itors. Overall, TMC114’s potency against MDR viruses is likely a combination of its extremely high affinity and
close fit within the substrate envelope.
Human immunodeficiency virus type 1 (HIV-1) protease, a
homodimeric enzyme with its active site located at the inter-
face between the two monomers, is responsible for posttrans-
lational processing of the viral Gag and Gag-Pol polyproteins
(11). Gag and Gag-Pol are cleaved in at least nine nonhomolo-
gous and asymmetric sites (6, 17, 32), releasing both structural
proteins and enzymes necessary for viral maturation. Hence,
inhibition of HIV-1 protease has been the target of antiviral
therapy in patients infected with the virus.
The structural basis for specificity of HIV-1 protease for its
substrates has been a focus in our laboratory (33, 35). We
solved the crystal structures of an inactive (D25N) variant of
the protease in complex with a series of peptides correspond-
ing to the native substrate cleavage sites (35). Analysis of these
structures has revealed that binding of the substrate to the
enzyme disrupts the symmetry of the protease dimer. In addi-
tion, specificity appears to be determined by the asymmetric
shape of the substrate rather than by a particular amino acid
sequence (35). The region occupied by the substrates, as de-
termined by calculations of their consensus volume, defines
what is referred to as a substrate envelope. Structural conser-
vation thus appears to be important (if not essential) for pro-
tease-substrate recognition.
All currently prescribed HIV-1 protease inhibitors, whose
structure-based design resulted from extensive investigations
of the conformation and function of HIV-1 protease, compete
with substrate by binding at the enzyme’s active site (44).
Although these compounds are chemically different, they oc-
cupy a highly overlapping volume, often with similar functional
groups positioned at similar locations in the active site. Con-
sequently, atoms of different inhibitors often contact the pro-
tease at the same residues. Mutations encoding amino acid
substitutions at these regions in the enzyme thus give rise to
multidrug-resistant (MDR) viruses, whose mutant proteases
no longer bind inhibitors effectively but maintain their ability
to recognize and cleave substrates. Due to the rapid replication
rate of the virus (7) and the possible infidelity of HIV-1 reverse
transcriptase, mutations are generated frequently, thus allow-
ing drug-resistant variants to emerge under the selective pres-
sure of patients undergoing protease inhibitor therapy (9, 36).
The generation and transmission of these MDR viruses has
created a major challenge for clinicians involved in the treat-
ment of HIV infection.
Examination of the Stanford HIV Drug Resistance Data-
base of HIV-1 infected-patient sequences of viral isolates
(http://hivdb.stanford.edu) reveals certain patterns of muta-
tional selection occurring with different protease inhibitor
treatments (39, 40). When we analyzed and compared these
patterns to the active-site regions occupied by the inhibitors,
we found that the primary drug-resistant mutations often oc-
curred at positions in the protease that are contacted by inhib-
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itor atoms protruding beyond the volume of the substrate en-
velope (20a). Of the five protease inhibitors that have been
prescribed for more than 1 year, amprenavir (APV) is the only
compound that fits predominately within this envelope. This
unique property of APV likely explains its pattern of selecting
viral mutants and drug resistance in patient viral isolates, which
is somewhat different than that of first-generation inhibitors.
APV binding to the wild-type (wt) protease is tighter by
about 1 order of magnitude than that of the first-generation
inhibitors: indinavir, nelfinavir, saquinavir, and ritonavir (43).
Thermodynamic studies have shown that APV binding is both
enthalpically and entropically favorable, whereas binding of
the above-mentioned inhibitors is mainly entropically driven
(42). These unique properties of APV could provide a tem-
plate for the development of new tightly binding HIV-1 pro-
tease inhibitors. In fact, the single-ringed tetrahydrofuran
(THF) group of APV was replaced with a double-ringed bis-
THF to design a protease inhibitor with an enhanced enthalpy
change (16, 45). However, this inhibitor, TMC126, in which the
carboxymethyl moiety substitutes for the four-amino group on
the aryl sulfonamide, lacked sufficient drug-like properties
such as solubility, metabolic stability, and oral absorption to be
a viable lead.
Work with TMC126, however, led to the selection of the
clinical candidate TMC114, a protease inhibitor that is chem-
ically related to both TMC126 and APV (Fig. 1) and is highly
potent against a wide range of drug-resistant viruses in vitro.
The 50% effective concentration of TMC114 against wt HIV
is 4.6 nM, with a selectivity index greater than 20,000 (10).
When compared with currently prescribed protease inhibitors,
TMC114 was substantially more active against over 1,600 pro-
tease-inhibitor-resistant clinical isolates (12). In a phase IIa
clinical trial, TMC114 boosted with ritonavir replaced a failing
protease regime in HIV-infected patients. After 14 days on this
functional monotherapy regime, these patients showed a me-
dian 1.35-log drop in viral load (2). Despite its minimal chem-
ical difference from APV, TMC114 was thus shown to perform
significantly better against drug-resistant viral isolates.
Our laboratory has used a MDR protease variant having the
amino acid substitutions L63P, V82T, and I84V (Fig. 2), for
which we have shown has weaker binding affinity to all of the
first-generation inhibitors in clinical use (N. M. King, unpub-
lished data), including APV. The substitutions at positions 82
and 84 affect the polarity and geometry, respectively, of the
active site. The mutation of I84V has the largest impact on
inhibitor binding, affecting all prescribed protease inhibitors.
The mutation L63P, located in the hinge region of the protein,
away from the active site, has been shown to compensate for
active-site mutations, restoring the impaired catalytic activity
of the enzyme (22, 38). Thus, this triple-mutant variant is a
useful prototype for studying MDR in HIV-1 protease.
In the present study, we determine and compare the X-ray
crystallographic structures and thermodynamics of APV and
TMC114 binding to the wt HIV-1 protease and our MDR
prototype variant. Detailed analyses of the structures of these
two inhibitors in complex with both proteases are used to
explain the reasons for differences in binding affinities as
determined by isothermal titration calorimetry. APV and
TMC114 binding are both shown to be enthalpically and en-
tropically driven, with TMC114 binding approximately 2 orders
of magnitude more tightly than APV. The three-dimensional
structures of these complexes reveal hydrogen bonds between
TMC114 and the protease that are not seen in the APV wt
complex. These additional hydrogen bonds may partially ex-
plain the extremely favorable enthalpy of binding for TMC114
FIG. 1. The chemical structures of APV and TMC114.
FIG. 2. Two orientations of the TMC1143X protease complex,
shown as ribbon diagrams. The two monomers of HIV protease are
shown in cyan and yellow with the side chains of the sites of mutation
shown, labeled, and highlighted in blue and green. TMC114 is shown
in magenta (15).
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compared to APV. In addition, both compounds are located
predominantly within the substrate envelope, which may ac-
count in part for the decreased susceptibility to existing drug-
resistant protease variants. Our analysis of the structural and
thermodynamic properties of these two inhibitors should pro-
vide insights for designing the next generation of inhibitors
with enhanced binding affinity to the wt enzyme and improved
efficacy against MDR viruses.
MATERIALS AND METHODS
Nomenclature. HIV-1 protease variants (wt or MDR [3X]) will be distin-
guished throughout this article by subscript acronyms. For example, TMC114wt
denotes a complex of the inhibitor TMC114 with the wt protease. Primes are
used to distinguish the two monomers in the protease dimer.
Protease gene construction. The MDR protease gene coding for the substitu-
tions L63P, V82T, and I84V was constructed using standard site-directed mu-
tagenesis of a synthetic protease variant (20). The synthetic protease also en-
coded the Q7K substitution to prevent autoproteolysis (37).
Protein expression and purification. The protease was expressed and purified
as previously described (20). The protein was refolded by rapid dilution in a
10-fold volume of 0.05 M sodium acetate buffer at pH 5.5, containing 10%
glycerol, 5% ethylene glycol, and 5 mM dithiothreitol (refolding buffer). To
reduce the volume, the protease was concentrated, followed by dialysis to remove
any remaining acetic acid. Protease used for crystallization was further purified
with a Pharmacia Superdex 75 fast-performance liquid chromatography column
equilibrated with refolding buffer.
Crystallization. Crystals were set up with a three- to fivefold molar excess of
inhibitor to protease, which ensures ubiquitous binding. The final protein con-
centration ranged from 0.5 to 2.5 mg ml1 in refolding buffer. The hanging-drop
method was used for crystallization as previously described (20). The reservoir
solution consisted of 126 mM phosphate buffer at pH 6.2, 63 mM sodium citrate,
and ammonium sulfate at a range of 25 to 33%.
Data collection. Data on the TMC1143X and TMC114wt complexes were
collected under cryocooled conditions with the synchrotron source at Advanced
Light Source at Lawrence-Berkeley National Laboratory, Berkeley, Calif. The
crystals were screened using robotics available at the 5.0.2 beam line. About 200
frames were collected from the best diffracting crystals, with each frame exposed
for 30 s and the wavelength tuned to 0.9 A˚. Data for the APV3X complex were
collected at room temperature, as the crystals were too large to freeze efficiently.
Crystals were mounted inside 0.3-mm-diameter capillary tubes, and data were
collected on an R-axis IV image plate system mounted on a Rigaku rotating
anode source. Two hundred frames were collected for this complex at 1-degree
intervals, with each frame exposed for 4 min. Denzo and ScalePack (23, 30) were
used to integrate and scale the raw data frames for all three complexes. Data
collection statistics are listed in Table 1.
Structure solution and crystallographic refinement. The method described in
Prabu-Jeyabalan et al. (34, 35) was used to solve and refine the APV3X complex.
The Fourier synthesis method was used for structure solution, with the substrate
structure, 1F7A, as the starting model. Structures were refined using the Crys-
tallography & NMR system (4). Refinement statistics for APV3X are given in
Table 1. For the TMC114 complexes, however, CCP4i (8) was used for all
crystallographic calculations. Structure solutions were obtained with the molec-
ular replacement package AMoRe (27), with 1F7A as the starting model. A
radius of integration of 20 A˚ and X-ray data within 4.0 to 2.5 A˚ were used for the
structure solution. Rigid body refinement was then carried out with Refmac5
(26), followed by initial-phase improvement to extend the entire data set with the
water-picking program ARP/wARP (24). Difference Fourier maps were com-
puted and inspected with the interactive graphic program O (18), and major
structural changes in the model, such as the inclusion of the inhibitor, were
incorporated. After manual model building, the real space refinement package
RSREF (5) was used to fine-tune the fit between the model and electron density
maps. After every RSREF run, restrained refinement with Refmac5 was under-
taken. Finally, crystallographic anisotropic temperature factors were refined. The
final refinement statistics are listed in Table 1.
Isothermal titration calorimetry. Thermodynamic parameters of inhibitor
binding were determined using an isothermal titration calorimeter, VP-ITC
(MicroCal Inc., Northampton, Mass.). The buffer used for all protease and
inhibitor solutions consisted of 10 mM sodium acetate (pH 5.0), 2% dimethyl
sulfoxide, and 2 mM Tris (2-carboxyethyl) phosphine. The binding affinities of
APV and TMC114 for both the wt and MDR proteases were obtained by the
displacement titration method, with either acetyl-pepstatin or indinavir as the
weaker binder (29, 41, 43). Indinavir (75 to 200 M) was used exclusively in
competition experiments with the mutant protease (6.3 to 11.5 M) and TMC114
(78 to 83 M). Pepstatin (250 to 300 M) provided the competing inhibitor for
all other assays, with a protease concentration of 15.6 to 22 M. For all dis-
placement experiments with wt protease, TMC114 and APV were used at con-
centrations of 56 and 250 M, respectively. Twenty injections (each, 10 l) of the
weak binder were injected into the calorimetric cell containing the protease, fol-
lowed by 29 injections (each, 10 l) of the tight binder. Direct titration experi-
ments were also performed with the tightly binding inhibitor to confirm the en-
thalpy changes obtained by the displacement method. Each experiment was
performed at least twice. Heats of dilution were subtracted from the correspond-
ing heats of reaction to obtain the heat due solely to inhibitor binding to the enzyme.
Data were processed using software kindly provided by B. Sigurskjold (41).
RESULTS
Overall structural features. The MDR HIV-1 protease vari-
ant with substitutions L63P, V82T, and I84V was crystallized in
complex with two inhibitors, APV and TMC114 (referred to as
APV3X and TMC1143X complexes, respectively). The wt pro-
tease was crystallized in complex with TMC114 only (referred
to as TMC114wt), since the APVwt structure has already been
solved (Protein Data Bank entry 1HPV) (19). Crystallo-
graphic statistics for these structures are listed in Table 1. The
TMC114 structures and APV3X crystallized in the space group
P212121, with similar cell dimensions and one dimer per asym-
metric unit. The APVwt structure is in the P61 space group, also
with one dimer per asymmetric unit and a resolution of 1.9 A˚
(19). Any deviations between structures arising as a result of
different crystal contacts are accounted for in the present analysis.
As shown in Table 1, the present structures were refined to
resolutions ranging from 2.2 to 1.2 A˚. The electron density for
all inhibitor and protease atoms was well ordered in each of the
TABLE 1. X-ray crystallographic data collection and refinement
statistics for the three inhibitor-protease complexes
Variable
Complex
TMC114wt TMC1143X APV3X
Resolution (Å) 1.20 1.35 2.20
Temperature (°C) 80 80 25
Mirror LBLa LBLa Osmic
Space group P212121 P212121 P212121
a (Å) 50.746 50.858 51.070
b (Å) 57.807 58.040 59.342
c (Å) 62.006 61.656 61.823
Z 4 4 4
Rmerge (%) 3.8 4.4 8.7
Completeness (%) 95.5 98.0 96.8
Total no. of reflections 302,022 256,671 49,950
No. of unique reflections 55,056 39,998 9,705
Rfactor (%) 14.1 16.8 20.3
Rfree (%) 17.9 20.0 24.4
No. of crystallographic waters 263 203 58
RMSDb in:
Bond lengths (Å) 0.004 0.005 0.007
Bond angles (°) 1.50 1.30 1.38
B factors (isotropic) RMSD
bonded (Å2)
Main chain 1.5 1.5 1.7
Side chain 3.0 3.0 2.9
I/I 25.0 13.5 5.9
PDB codec 1T3R 1T7I 1T7J
a Data collected at Advanced Light Source, Lawrence-Berkeley National Lab-
oratory.
b RMSD, root mean square deviation.
c PDB, Protein Data Bank.
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three structures. The mutated side chains also showed unam-
biguous electron density, with two different conformations
clearly demonstrated in some cases (see below). Contrary to
most of the previous structures of complexes between the pro-
tease and first-generation inhibitors solved in our laboratory,
no alternate conformations were observed for residues I50 and
G51 located at the tips of the flaps (20; King, unpublished).
Minor structural adjustments due to the different inhibitors
bound in the active site or to mutations in the protease were
identified between complexes and will be described below.
TMC114wt complex. The complex between the wt protease
and the tightly binding inhibitor TMC114 was refined to high
resolution (1.20 A˚), allowing a very detailed structural analysis.
The Rfactor for this complex was 14.1%, with 263 water mole-
cules clearly defined. The inhibitor had strong electron density
and was uniquely modeled in one conformation. Alternate
conformations were observed for active-site residues I47, V82,
V32, and V82. Two conformations were also observed for
residues L19, E21, C95, M46, and E65.
TMC1143X complex. The crystal complex between the MDR
HIV protease variant and TMC114 diffracted to a resolution of
1.35 A˚, with an Rfactor value of 16.8%. Protease residues that
were present in two conformations and within van der Waals
distance of the inhibitor molecule included R8 and T82 from
both monomers, as well as I47 and L23. Nine additional resi-
dues located outside of the active site also had two conformations.
APV3X complex. Data for the APV3X complex were col-
lected with our local instrumentation at room temperature,
and therefore its resolution is somewhat less than that of the
TMC114 complexes. However, the APV3X structure’s resolu-
tion of 2.2 A˚ was sufficient for comparison with the other
structures. The inhibitor molecule was modeled in one confor-
mation, except for its N-isobutyl group, which has two orien-
tations. The 2 angle in one conformer is 53° and 131° in the
other. All residues in the active-site region were uniquely mod-
eled in one conformation, indicating stability in this area of the
complex. However, two conformations were observed for res-
idues I15, Q18, E34, E35, and I64 and for residues N37, M46,
and I64, all located outside the inhibitor binding site.
Structural comparisons between wt complexes. Important
differences were observed in hydrogen-bonding patterns be-
tween the TMC114wt and APVwt structures. Figure 3 shows
hydrogen bonding between atoms in the protease active site
and atoms in the inhibitor, including those mediated by water.
A highly conserved water molecule tetrahedrally coordinated
the backbone nitrogen atoms in I50 of both monomers at the
tips of the flaps to O2 and O5 of the inhibitors. Replacement
of the single-ringed THF group in APV with the double-ringed
bis-THF group in TMC114 (Fig. 1) resulted in additional hy-
drogen bonds in the TMC114wt complex not seen in the APVwt
structure. As seen in Table 2 and Fig. 3c, the O7 oxygen in the
added ring of TMC114 was within hydrogen-bonding distance
of both the backbone nitrogen (2.9 A˚) and one of the carboxyl
oxygens (3.3 A˚) of D29. Furthermore, this added ring ap-
peared to pull that end of the inhibitor molecule closer to that
region of the active site.
The most significant differences between the wt protease
complexes with APV and TMC114 were in the lengths of the
hydrogen bonds with the protease. The largest differences were
between the O6 oxygen of the inhibitors and the backbone
nitrogens of residues D29 and D30 and between the N1 nitro-
gen of the inhibitors and the backbone oxygen of G27 (Table
2 and Fig. 3). In the TMC114wt complex (Fig. 3a), these dis-
tances were all 3.1 A˚ for D29, D30, and G27, whereas in the
APVwt complex (Fig. 3b) the corresponding distances were 3.5,
3.5, and 3.6 A˚, too far to easily form strong hydrogen bonds. At
the other side of the active-site cleft, an additional hydrogen
bond was evident in the TMC114wt complex: the N3 nitrogen
of TMC114 was 3.1 A˚ from the carbonyl oxygen of D30,
whereas the corresponding distance was 3.6 A˚ in the APVwt
structure. Thus, at least six hydrogen bonds occurred between
the wt protease and TMC114, but not APV, likely resulting in
the TMC114wt complex being more stable than the APVwt
complex. This is evident in Fig. 3c, where the two wt complexes
are superimposed; TMC114 is shifted slightly relative to APV,
allowing TMC114 to form more and tighter hydrogen bonds.
In addition, most of the hydrogen-bonding interactions between
TMC114 and the protease involved main-chain atoms located
at the bottom of the active-site cleft, thus decreasing the effects
of mutations occurring in that region of the protease.
Structural comparison between the wt and MDR complexes.
Flexibility in both proteins and ligands appeared to compen-
sate for any potential reduction in interactions resulting from
the mutations. For example, the rotatable bond of the N-
isobutyl group in TMC114 and APV allowed for conforma-
tional adjustments in the ligand. This flexibility is beneficial for
the inhibitor, since this moiety faces residue 84 in the active
site, a common site of drug-resistant mutation. Different ori-
entations of the N-isobutyl group can be seen in the four
complexes (Fig. 4): in the two TMC114 structures, the N-
isobutyl group has the same orientation, which differs from
those in each APV structure. This group is within 4.2 A˚ of I84
in TMC114wt and thus makes van der Waals contacts (Fig. 4a).
These interactions are reduced, however, in APVwt where the
N-isobutyl group is rotated around 1 (Fig. 4b). A loss in van
der Waals interactions was also seen in the TMC1143X struc-
ture, where the I84V substitution changed the volume and
geometry of the active site (Fig. 4c). In the second monomer,
however, the side chain of V84 underwent a rotation around
1, at least partially filling this gap. The APV3X complex did
not appear to have suffered as great a loss in van der Waals
interactions, since the N-isobutyl group took on two confor-
mations, thus maintaining these interactions with V84 (Fig.
4d). In the second monomer, the interactions with residue 84
were primarily maintained, due to the shift and tilt in APV’s
position in the active site (Fig. 4f).
The positions of the loop regions between residues 79 and 81
(the 80s loops) in the protease active site sometimes change
between structures, due to relative shifts and tilts in the bound
ligand (1, 3, 20, 25). We have observed these changes between
both wt structures and their corresponding mutant complexes.
The shift of the ligand in TMC1143X by an average of 0.16 A˚
relative to its position in the wt structure coincided with a
repositioning of the 80s loop of one monomer (Fig. 4e), but
very little change was observed in the same region of the other
monomer. The shift and tilt of APV in the mutant structure
relative to the wt complex paralleled the shift of both 80s loops
(Fig. 4f). The positions of the inhibitor in APVwt and in APV3X
differed by an average of 0.34 A˚ and an average angle of 6.25°.
With this repositioning of the ligand, the 80s loop in one
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monomer moved towards the inhibitor, whereas the same re-
gion in the other monomer moved away. Thus, the 80s loops
adjusted to each of the inhibitors, depending on the specific
interactions within that complex.
The locations and lengths of hydrogen bonds between the
inhibitor and protease in the TMC1143X complex were very
similar to those for the TMC114wt structure (Table 2). Al-
though the ligand’s position shifted slightly within the active
FIG. 3. Stereo pairs showing the network of hydrogen bonds between (a) the TMC114wt complex (note that the hydrogen bonds are the same
between the wt and MDR protease complexes with TMC114) (Table 2), (b) the APVwt complex, (c) superimposition of TMC114wt (in magenta
and purple with hydrogen bonds in black) and APVwt (in cyan and gray with hydrogen bonds in yellow), and (d) the APV3X complex (15).
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site of the TMC1143X structure (Fig. 4e), this shift was not
sufficient to disrupt these interactions. In addition, a new in-
teraction was seen between protease and inhibitor in the
TMC1143X complex. One of the conformations of T82 was
oriented such that it made OH- interactions with the phenyl
ring of the inhibitor. However, the T82 side chain in APV3X
points away from the inhibitor (Fig. 4f) and thus did not in-
teract with APV’s phenyl ring, as in the TMC1143X structure
(Fig. 4e). Otherwise, as shown in Table 2 and Fig. 3d, the hy-
drogen-bonding pattern for the APV3X complex more closely
resembled that of the TMC114 complexes than the APVwt
complex. Rearrangements in the APV3X complex resulted in
closer hydrogen bonds between ligand and active-site atoms
than in the APVwt structure. In APV3X, the O6 oxygen of APV
was 3.2 and 3.1 A˚ from the amide nitrogens of D29 and D30,
respectively. In the APVwt structure, on the other hand, these
FIG. 3—Continued.
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distances were both 3.5 A˚, which are long and therefore weak
for hydrogen bonds. The tilt in the ligand of the APV3X struc-
ture relative to its position in the APVwt complex (Fig. 4f) was
also demonstrated in the distance between the N3 nitrogen of
APV and the main-chain oxygen atom of D30 at the other side
of the active-site cleft. The N3 nitrogen was closer to the car-
bonyl oxygen (3.3 A˚) in APV3X than in APVwt (3.6 A˚) (Table
2 and Fig. 3d). The N3 nitrogen end of the ligand was farther
away from the primed monomer in the APVwt structure than
in the APV3X complex. Thus, adjustments demonstrated in the
MDR APV3X complex were not seen when TMC114 was
bound in the active site.
Comparison with the substrate envelope. Our laboratory has
hypothesized that HIV-1 protease recognizes an asymmetric
shape, or envelope, adopted by its substrates rather than a
particular amino acid sequence (35). If the substrate envelope
was superimposed on the inhibitor structures of TMC114 and
APV, only a few atoms of each inhibitor protruded beyond the
envelope (Fig. 5). Residues 25, 27, 28, 29, and 30 were all lo-
cated at the bottom of the active-site cleft, and residues 47, 49,
and 50 were in the flaps at the top of the active site. Residues
32 and 84 are located on both sides of the active site. These
residues represent potential sites where drug-resistant muta-
tions impacting TMC114 and APV could occur.
Thermodynamics. Isothermal titration calorimetry was used
to determine the thermodynamics of binding between the wt
FIG. 4. Inhibitor interactions with residues 82 and 84 in the various protease complexes (15). (a) TMC114wt complex showing the van der Waals
interactions between TMC114 and I84. (b) APVwt complex showing the van der Waals interactions between APV and I84. (c) TMC1143X complex
showing the van der Waals interactions between TMC114 and V84. (d) APV3X complex showing the van der Waals interactions with V84. (e)
Superposition of TMC114wt (in gray and cyan) and TMC1143X (in purple-yellow and magenta) complexes. Note the additional OH- hydrogen
bond made by T82. (f) Superposition of APVwt and APV3X complexes. Note the conformational variability of the N-isobutyl group (arrow).
TABLE 2. Hydrogen-bonding distances between protease and
inhibitor atoms in APV and TMC114 structures
Protease
atom
Inhibitor
atom
Distance (Å) for:
TMC114wt TMC1143X APVwt APV3X
Asp 29 N O6 3.1 3.1 3.5 3.2
Asp 30 N O6 3.1 3.1 3.5 3.1
Asp 29 N O7 2.9 2.9
Asp 29 OD2 O7 3.3 3.3
Water O2 2.8 (W4)a 2.8 (W2) 3.0 (W201) 2.8 (W8)
Gly 27 O N1 3.1 3.1 3.6 3.5
Asp 25 OD1 O3 3.0 2.5 2.7 2.6
Asp 25 OD2 O3 2.5 2.9 2.8 3.1
Asp 25 OD1 O3 2.6 2.6 2.6 2.7
Asp 25 OD2 O3 3.3 3.2 3.1 2.9
Water O5 2.9 (W4) 2.8 (W2) 2.8 (W201) 2.9 (W8)
Water O4 3.4 (W201) 3.4 (W8)
Asp 30O N3 3.1 3.2 3.6 3.3
Water N3 3.0 (W234) 2.9 (W86) 3.4 (W120)
Asp 30 OD2 N3 3.2
aThe corresponding water number is in parentheses.
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and MDR proteases and the inhibitors APV and TMC114.
Table 3 lists the thermodynamic parameters of binding for
each protease-inhibitor pair. Both inhibitors bound with favor-
able enthalpy and entropy changes, with the enthalpic contri-
bution being particularly high for TMC114’s binding to the wt
enzyme (H 	 12.1 kcal/mol TS 	 3.1 kcal/mol). The
change in free energy resulted in tight binding of both inhibi-
tors, as indicated by dissociation constants of 3.9 
 1010 M
and 4.5 
 1012 M for APV and TMC114, respectively. As
shown in Table 3, the binding constant for TMC114 to the wt
protease was approximately 87-fold greater than APV, with a
difference in binding enthalpy of 4.8 kcal/mol. Thus, the bind-
ing of TMC114 to the wt protease was more enthalpically
driven than binding of APV. For the binding of APV, the
enthalpic and entropic contributions to the total free energy of
binding were more similar (H 	 7.3 kcal/mol; TS 	
5.3 kcal/mol). The loss of favorable entropy by 2.2 kcal/mol
for TMC114 relative to APV, the underlying basis of which is
not clear, was compensated for by the significantly more-favor-
able enthalpy change of 4.8 kcal/mol. Thus, enthalpy appeared
to drive the increased binding affinity of TMC114.
TMC114 binding to the MDR 3X mutant protease was 13.3
times less tight than its binding to the wt enzyme. Although the
enthalpy change is less favorable by 2.1 kcal/mol, the entropic
contribution becomes slightly more favorable (TS 	 0.6
kcal/mol). APV binding to the mutant protease is less compro-
mised than that of TMC114 (Table 3); the ratio of binding
affinities for APV (Kd 3X/Kd wt) is 5.1, with nearly equivalent
losses in enthalpic (0.3 kcal/mol) and entropic (0.6 kcal/mol)
contributions to free energy. The I84V substitution in the mu-
tant protease, which reduces van der Waals interactions with
the inhibitor, is likely the main reason for the reduced binding
affinity of both APV3X and TMC1143X (Fig. 4). The I84V
substitution had less of an effect on the binding of APV, mainly
because of the strong interactions with D29 and D30 in this
complex. These interactions compensated for some of the loss
in van der Waals interactions. This observation also supports
the importance of these interactions in increasing binding af-
finity. However, although TMC114 lost a larger percentage of
FIG. 5. Substrate envelope (35) of HIV protease shown in blue
(28), superimposed on the structures of (a) TMC114 and (b) APV. The
atoms of each of the inhibitors that protrude from the envelope are
shown in red and labeled. HIV protease residues that are within van
der Waals contact of these atoms are also labeled.
TABLE 3. Binding thermodynamics of APV and TMC114 at 20°C
Pair Ka (M1) Kd (M) H (kcal/mol) TS (kcal/mol) G (kcal/mol)
Wild type
APV 2.5 
 109 3.9 
 1010 7.3 5.3 12.6
TMC114 2.2 
 1011 4.5 
 1012 12.1 3.1 15.2
KdAPV/Kd TMC114 H (kcal/mol) TS (kcal/mol) G (kcal/mol)
86.7 4.8 2.2 2.6
3x Mutant Kd (M) H (kcal/mol) TS (kcal/mol) G (kcal/mol)
APV 5.1 
 108 2.0 
 109 7.0 4.7 11.7
TMC114 1.7 
 1010 6.0 
 1011 10.0 3.7 13.7
KdAPV/KdTMC114 H (kcal/mol) TS (kcal/mol) G (kcal/mol)
33.3 3.0 1.0 2.0
Kd3
/Kdwt H (kcal/mol) TS (kcal/mol) G (kcal/mol)
APV 5.1 0.3 0.6 0.9
TMC114 13.3 2.1 0.6 1.5
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its total binding affinity, it still bound more than 33-fold tighter
to the MDR protease than did APV.
DISCUSSION
Our analyses of the binding and structure of the HIV-1
protease inhibitors APV and TMC114 provide a rationale for
the potency that renders them more advantageous than the
first-generation inhibitors. Both compounds bind to the pro-
tease with high affinity, yet TMC114 is a particularly tight
binder, due to additional strong interactions with main-chain
atoms at the bottom of the active site. TMC114 binding is
mainly enthalpically driven, whereas the enthalpic and en-
tropic contributions to the binding of APV are nearly equiva-
lent. TMC114 binds almost 2 orders of magnitude more tightly
than APV but protrudes further from the substrate envelope.
This protrusion allows TMC114 to form more hydrogen bonds,
which likely increase its affinity for the protease. Yet, those
same protruding atoms may cause it to take a more substantial
decrease in its binding constant when it binds to drug-resistant
variants. However, since TMC114 already starts with an ex-
tremely tight affinity, it can sustain a substantial decrease in its
binding constant without compromising its activity, allowing it
to remain effective.
In a modeling study of APV and the closely related HIV-1
protease inhibitor TMC126 (29), Ohtaka et al. attribute the
highly favorable binding enthalpy of TMC126 to strong inter-
actions and sequestered water molecules. The strong interac-
tions found between TMC126 and D29 and D30 at the bottom
of the active-site cleft agree with our analyses of X-ray struc-
tures of TMC114. We found an additional hydrogen-bonding
interaction with the backbone carbonyl oxygen of G27, which is
not seen in the wt APV structure. Furthermore, the more-
favorable binding enthalpy of TMC126 was attributed to its
ability to sequester more water molecules than APV (29). Our
high-resolution X-ray crystallographic structures did not, how-
ever, reveal a significantly different number of water molecules
at the binding sites of the TMC114, suggesting that sequestra-
tion of water molecules may not contribute to the highly fa-
vorable enthalpy change for the binding of TMC114. Strong,
direct protease inhibitor interactions therefore likely contrib-
ute predominantly to the very high binding affinity of this
inhibitor.
TMC114 and APV fit within the substrate envelope better
than any currently prescribed protease inhibitor. HIV-1 pro-
tease residues that are contacted by an inhibitor at sites where
it protrudes from the substrate envelope are potential sites of
drug-resistant mutations. For TMC114, these residues include
G27, A28, D29, D30, V32, I47, I50, and I84. Several of these
residues, G27, A28, and D29, have never or rarely been seen
to mutate in the current Stanford HIV Drug Resistance Data-
base (http://hivdb.stanford.edu) (39, 40). In vitro studies have
shown that the closely related HIV-1 protease inhibitor TMC126
selects for active-site mutations at A28 and I50, as well as for
mutations remote from the active site (45). Alanine at position
28 in HIV-1 protease is highly conserved; substitution at A28
occurred in only four of 6,099 HIV-1 infected patients (39, 40;
http://hivdb.stanford.edu). Since TMC114 and TMC126 are so
similar in structure, they are likely to have the same fit in the
active site and to contact the same protease residues. Thus,
although TMC114 contacts such commonly mutating protease
residues as D30, V32, I47, I50, and I84, mutations at these sites
have so far not been selected in vitro when wt HIV-1 is exposed
to increasing concentrations of inhibitor (13). However, stud-
ies are under way to investigate the susceptibility to TMC114
of viruses having preexisting protease mutations. APV, on the
other hand, with its slightly different binding mode and lower
binding affinity, does in fact select in vitro for active-site mu-
tations at I47, I50, and I84 (31).
Since TMC114 binds so tightly, the simultaneous occurrence
of multiple mutations at several of these sites may be necessary
before the virus becomes resistant to the inhibitor. However, if
TMC114 effectively suppresses viral turnover, the opportunity
for selection of resistance will be greatly decreased. If resistant
variants arise which have multiple mutations, substrate binding
may also be affected. The further evolution of substrate sites
would be required for the virus to survive. Such coevolution
has occasionally been seen, although it has been primarily
limited to the NC-p1 cleavage site. In this case, the P2 residue
mutates from an alanine to a valine in the presence of the
V82A protease drug-resistant mutation (14, 21, 46). These
results are encouraging in that the virus may have more diffi-
culty in developing resistance to TMC114 than to other pro-
tease inhibitors; however, with the heterogeneity of HIV in
vivo this will be confirmed only when extensive clinical trials
are concluded.
Our findings suggest that the potency of TMC114 is due to
a combination of two factors: (i) its extremely tight binding
(Kd 	 4.5 pM) and (ii) its close fit within the substrate enve-
lope. The promise of TMC114 as a next-generation protease
inhibitor is supported by our structural and thermodynamic
analyses of its unique properties, which provide a framework
for the design of new inhibitors exhibiting potency on both wt
and MDR viruses.
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